GTS Securities’s SAB Biotherapeutics Warrant SABSW Stock Holding History

GTS Securities’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$537	Buy	41,301 +300	+0.7%	+$6	﹤0.01%	1312
2026 Q1	$1.07K	Sell	41,001 -100	-0.2%	-$3	﹤0.01%	1468
2025 Q4	$1.03K	Buy	+41,101	New	+$1.25K	﹤0.01%	1346

Other funds holding SABSW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

GTS Securities's SABSW Position: Q2 2026 in Review

GTS Securities increased its SAB Biotherapeutics Warrant (SABSW) stake by 0.73% in Q2 2026, buying an estimated $6 and bringing the position to 41,301 shares worth $537. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

GTS Securities first reported a position in SABSW in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.07K in Q1 2026. 8 funds tracked by Wall St. Rank hold SABSW as of Q2 2026.

GTS Securities held 41,301 shares of SAB Biotherapeutics Warrant worth $537 as of Q2 2026.
GTS Securities bought 300 SAB Biotherapeutics Warrant shares in Q2 2026, an estimated $6.
SAB Biotherapeutics Warrant made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1312 holding.
GTS Securities first reported a position in SAB Biotherapeutics Warrant in Q4 2025 and has held it in 3 quarters since.
GTS Securities's SAB Biotherapeutics Warrant position peaked at $1.07K in Q1 2026.
8 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.